LEARN MORE ABOUT
PSMA+ metastatic castration-resistant prostate cancer
mCRPC, metastatic castration-resistant prostate cancer; PSMA+, prostate-specific membrane antigen positive.
What is the most important information I should know about PLUVICTO?
Use of PLUVICTO involves exposure to radioactivity. Long-term, accruing radiation exposure is associated with an increased risk for cancer...
What is PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan)?
PLUVICTO is a radiopharmaceutical used to treat adults with an advanced cancer called prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) that...